Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RoxyBond Gets US Advisory Panel OK For Abuse-Deterrent Claim Despite Excipient Concerns

Executive Summary

Members unanimously endorse product and mostly supported abuse-deterrent language; several panelists suggest warning about possible harmful effects of excipients by abusing product intravenously.

Advertisement

Related Content

RoxyBond Clears US FDA With Abuse-Deterrent Properties, But No REMS Yet
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Abuse-Deterrent Opioids: Postmarketing Data Eyed As Development ‘Anchor’
Recent And Upcoming FDA Advisory Committee Meetings
Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse
Opioid Abuse-Deterrence: Immediate Release Formulation Is Chance For US FDA To Reassess Goal Posts

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel